In this podcast, Hugh Davis, Chief Business Officer at Frontage Laboratories, discusses how bioanalytical laboratories like Frontage keep up with the latest therapies, challenges of a clinical development program design, bioanalytical considerations in developing assays, and the future of this field in the next 5-10 years.

​Frontage has developed a next-generation sequencing (NGS)-based method to rapidly determine the genotype of 300+ genes involved in ADME, called the Frontage PGx NGS Test.

In this white paper, we show testing of two critical parameters for the method validation of Gyrolab: 1) carryover contamination and 2) after MRD (minimum required dilution) stability.